Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)

被引:3
|
作者
Schwarz, Andrea [1 ,2 ,3 ,4 ,5 ]
Demuth, Ilja [1 ,2 ,3 ,4 ,6 ]
Landmesser, Ulf [7 ,8 ,9 ]
Haghikia, Arash [7 ,8 ,9 ]
Konig, Maximilian [1 ,2 ,3 ,4 ]
Steinhagen-Thiessen, Elisabeth [1 ,2 ,3 ,4 ,10 ]
机构
[1] Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Including Div Lipid Metab, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Humboldt Univ, Biol Aging Working Grp, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Charite Univ Med Berlin, Div Cardiol, Dept Pediat, Berlin, Germany
[6] BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany
[7] Charith Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany
[9] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
[10] Univ Rostock, Inst Clin Chem & Lab Med, Rostock, Germany
关键词
LDL-cholesterol; Treatment goal achievement; Familial hypercholesterolemia; Lipoprotein (a); Coronary artery disease; Lipid-lowering treatment; Family history; LIPID-MODIFYING THERAPY; CARDIOVASCULAR RISK; HEART-DISEASE; ASSOCIATION; EZETIMIBE; HISTORY; ATORVASTATIN; SIMVASTATIN; GUIDELINE; DIAGNOSIS;
D O I
10.1186/s12944-022-01708-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Although potent lipid-lowering therapies are available, patients commonly fall short of recommended low-density lipoprotein cholesterol (LDL-C) levels. The aim of this study was to examine the relationship between familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] and LDL-C goal attainment, as well as the prevalence and severity of coronary artery disease (CAD). Moreover, we characterized patients failing to meet recommended LDL-C goals. Methods We performed a cross-sectional analysis in a cohort of patients undergoing cardiac catheterization. Clinical FH was determined by the Dutch Clinical Lipid Network Score, and Lp(a) >= 50 mg/dL (approximate to 107 nmol/L) was considered elevated. Results A total of 838 participants were included. Overall, the prevalence of CAD was 72%, and 62% received lipid-lowering treatment. The prevalence of clinical FH (probable and definite FH) was 4%, and 19% had elevated Lp(a) levels. With 35%, LDL-C goal attainment was generally poor. Among the participants with clinical FH, none reached their LDL-C target. Among patients with elevated Lp(a), LDL-C target achievement was only 28%. The prevalence and severity of CAD were higher in participants with clinical FH (86% prevalence) and elevated Lp(a) (80% prevalence). Conclusion Most participants failed to meet their individual LDL-C goals according to the ESC 2016 and 2019 guidelines. In particular, high-risk patients with clinical FH or elevated Lp(a) rarely met their target for LDL-C. The identification of these patients and more intense treatment approaches are crucial for the improvement of CAD primary and secondary prevention.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)
    Andrea Schwarz
    Ilja Demuth
    Ulf Landmesser
    Arash Haghikia
    Maximilian König
    Elisabeth Steinhagen-Thiessen
    Lipids in Health and Disease, 21
  • [2] Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry
    Schmidt, Nina
    Dressel, Alexander
    Grammer, Tanja B.
    Gouni-Berthold, Ioanna
    Julius, Ulrich
    Kassner, Ursula
    Klose, Gerald
    Koenig, Christel
    Koenig, Wolfgang
    Otte, Britta
    Parhofer, Klaus G.
    Reinhard, Wibke
    Schatz, Ulrike
    Schunkert, Heribert
    Steinhagen-Thiessen, Elisabeth
    Vogt, Anja
    Laufs, Ulrich
    Maerz, Winfried
    ATHEROSCLEROSIS, 2018, 277 : 314 - 322
  • [3] Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia
    Tada, Hayato
    Nomura, Akihiro
    Nohara, Atsushi
    Usui, Soichiro
    Sakata, Kenji
    Hayashi, Kenshi
    Fujino, Noboru
    Takamura, Masayuki
    Kawashiri, Masa-aki
    ATHEROSCLEROSIS, 2023, 371 : 61 - 66
  • [4] Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia
    Tada, H.
    Nomura, A.
    Usui, S.
    Sakata, K.
    Takamura, M.
    Kawashiri, M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [5] LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG MALAYSIAN DYSLIPIDEMIC PATIENTS
    AL-khateeb, Alyaa
    Mohamed, Mohd Sapawi
    Imran, Kamarul
    Ibrahim, Suhairi
    Zilfalil, B. A., I
    Yusof, Zurkurnai
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2011, 42 (02) : 388 - 394
  • [6] Therapeutic modalities following low-density lipoprotein cholesterol goal attainment
    Miller, Michael
    FUTURE LIPIDOLOGY, 2006, 1 (02): : 131 - 133
  • [7] Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia
    Nomura, Akihiro
    Sato, Takehiro
    Tada, Hayato
    Kannon, Takayuki
    Hosomichi, Kazuyoshi
    Tsujiguchi, Hiromasa
    Nakamura, Hiroyuki
    Takamura, Masayuki
    Tajima, Atsushi
    Kawashiri, Masa-aki
    JOURNAL OF HUMAN GENETICS, 2021, 66 (11) : 1079 - 1087
  • [8] Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia
    Akihiro Nomura
    Takehiro Sato
    Hayato Tada
    Takayuki Kannon
    Kazuyoshi Hosomichi
    Hiromasa Tsujiguchi
    Hiroyuki Nakamura
    Masayuki Takamura
    Atsushi Tajima
    Masa-aki Kawashiri
    Journal of Human Genetics, 2021, 66 : 1079 - 1087
  • [9] LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL IMMUNOPHERESIS IN TREATING 3 PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    KUKHARCHUK, VV
    KONOVALOV, GA
    KURDANOV, KA
    VEDERNIKOV, AY
    POKROVSKY, SN
    ALFERYEV, AM
    KHASHIMOV, KA
    ARTIFICIAL ORGANS, 1988, 12 (03) : 277 - 277
  • [10] Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis
    Nenseter, Marit S.
    Narverud, Ingunn
    Graesdal, Asgeir
    Bogsrud, Martin P.
    Aukrust, Pal
    Retterstol, Kjetil
    Ose, Leiv
    Halvorsen, Bente
    Holven, Kirsten B.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (02) : 109 - 116